Testing has been hard to read. Several figures have pointed to Red Bull as being on top form. The team disagrees. Charles Leclerc warns one F1 rival “hiding a massive amount” at Bahrain test Charles ...

Make sure you follow the third day of F1 testing live with us on PlanetF1.com, with our reporters on the ground in Bahrain. Come the end of today, we will have reached the halfway point of official ...

Teams have gathered in Bahrain for two weeks of pre-season testing ahead of the highly-anticipated 2026 F1 season. Preparations are ramping up for F1’s brave new era of regulations, with all 11 teams ...

Cisco shares plunged 12% Thursday as the company's margins face pressure from rising memory prices. The drop is the company's largest in four years. The memory shortage, driven by increased demand for ...

Charles Robbins, Chairman & CEO, stated that "Q2 was a very strong quarter with revenue and earnings per share both growing double digits and coming in above the high end of our guidance ranges." He ...

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Cisco Systems (NasdaqGS:CSCO) introduced its Silicon One ...

TCIL bans Cisco India from tenders for 2 years due to anti-competitive practices. Existing contracts with Cisco remain unaffected by TCIL's order TCIL claims Cisco didn't provide bid documents for ...

Apple Rolls Out iOS 26.3 Security Test to Beta Users Your email has been sent Apple has quietly launched a security testing system that could transform how iPhones receive critical updates. The tech ...

The second-best-selling Tesla of them all failed to secure the Top Safety Pick+ award for 2025, primarily due to its performance in the moderate overlap front crash test. In this crash scenario, the ...

Forbes contributors publish independent expert analyses and insights. James Morris covers the rapidly growing world of electric vehicles. Swedish brand Polestar may have been having problems with its ...

Rezolute’s stock has plunged 87% after the company’s rare disease drug flunked the final clinical test ahead of a planned approval application. The company had been evaluating ersodetug as a treatment ...